Short Interest in Genfit S.A. (OTCMKTS:GNFTF) Expands By 367.5%

Genfit S.A. (OTCMKTS:GNFTF) saw a large increase in short interest in the month of May. As of May 31st, there was short interest totalling 57,500 shares, an increase of 367.5% from the May 15th total of 12,300 shares. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ∞ days.

Genfit Price Performance

Shares of Genfit stock opened at $3.54 on Thursday. The stock has a 50-day moving average price of $3.54 and a 200 day moving average price of $3.80. Genfit has a 1 year low of $2.95 and a 1 year high of $5.55.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.